Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation

Carl Högberg1, David Erlinge, Oscar O Braun

  • 1Department of Cardiology, Lund University, Lund, Sweden. carl.hogberg@med.lu.se

Thrombosis Journal
|February 25, 2009
PubMed

Insights

Mild hypothermia did not reduce platelet aggregation and actually increased it after clopidogrel treatment. This suggests dual antiplatelet therapy may be necessary for patients undergoing mild hypothermia.

Area of Science:

  • Cardiovascular Research
  • Hematology
  • Pharmacology

Background:

  • Mild hypothermia is a standard treatment for cardiac arrest patients.
  • A common assumption is that hypothermia reduces platelet aggregation.
  • The effect of clopidogrel on platelet aggregation during hypothermia requires investigation.

Purpose of the Study:

  • To investigate the impact of mild hypothermia on platelet aggregation.
  • To determine how clopidogrel affects platelet aggregation under hypothermic conditions.

Main Methods:

  • Evaluated platelet reactivity at 37°C and 33°C using light transmission aggregometry and VASP.
  • Assessed blood from healthy volunteers before and after a 600 mg clopidogrel loading dose.
  • Utilized various agonists including ADP, collagen, and U46619.

Main Results:

  • Hypothermia did not attenuate, and sometimes increased, platelet aggregation induced by various agonists.
  • ADP-induced platelet aggregation was significantly higher at 33°C compared to 37°C after clopidogrel administration.
  • Reduced responsiveness to clopidogrel during hypothermia could be reversed by a P2Y12 antagonist.

Conclusions:

  • Mild hypothermia does not inhibit platelet aggregation and can enhance ADP-stimulated aggregation post-clopidogrel.
  • Dual antiplatelet therapy (aspirin and a P2Y12 antagonist) is likely necessary for patients on mild hypothermia.
  • Future ADP blockers might offer benefits in this patient population.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...